FDA Law Blog - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
FDA Law Blog

FDA Law Blog

Publication
0 followers

Practitioner-written analysis of FDA/US regulatory policy, enforcement, approvals, and litigation.

Recent Posts

Surprise! Fifth Circuit Rejects DEA’s Longstanding Interpretation of a Pharmacist’s “Corresponding Responsibility” And “Usual Course of Professional Practice” Regulations
News•Feb 26, 2026

Surprise! Fifth Circuit Rejects DEA’s Longstanding Interpretation of a Pharmacist’s “Corresponding Responsibility” And “Usual Course of Professional Practice” Regulations

The Fifth Circuit rejected the DEA’s long‑standing reading of the pharmacist’s “corresponding responsibility” and “usual course of professional practice” regulations, ruling that liability requires proof a prescription was invalid when issued and that the pharmacist actually knew it was invalid. The court clarified that the “usual course” refers to bona‑fide pharmacy practice, not a state‑law standard of care. This decision overturns decades of DEA enforcement precedent and creates a circuit split with the Sixth Circuit. The case is now remanded for the DEA to reassess Neumann Pharmacy’s registration revocation.

By FDA Law Blog
The Government’s Warning Shot? FDA and HHS Turn Up the Pressure on Compounding
News•Feb 23, 2026

The Government’s Warning Shot? FDA and HHS Turn Up the Pressure on Compounding

The FDA, backed by HHS, issued a stark warning to compounding pharmacies that market GLP‑1 products such as semaglutide, after Hims & Hers promoted a compounded Wegovy copy. A press release announced intent to restrict non‑approved GLP‑1 APIs and referred...

By FDA Law Blog
Rare Disease Month Developments – Part 3: The Ugly (Just Kidding) – See You at Rare Disease Week
News•Feb 20, 2026

Rare Disease Month Developments – Part 3: The Ugly (Just Kidding) – See You at Rare Disease Week

Rare Disease Week convenes on Capitol Hill, bringing patients, advocates, regulators, and industry together to shape policy for rare disease therapies. Hyman, Phelps & McNamara will be prominently represented, highlighted by Frank Sasinowski receiving the EveryLife Foundation’s Abbey Lifetime Achievement...

By FDA Law Blog
Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda...
News•Feb 17, 2026

Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda...

Congress renewed the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program, extending it to September 30 2029 and eliminating the dual sunset dates. The FDA released its Rare Disease Innovation Hub’s 2026 Strategic Agenda, allocating $1 million in funding and outlining plans...

By FDA Law Blog
Who Qualifies for the New FDA PreCheck Pilot Program?
News•Feb 16, 2026

Who Qualifies for the New FDA PreCheck Pilot Program?

The FDA has opened submissions for its PreCheck Pilot Program, targeting new U.S. drug‑manufacturing facilities that will begin construction by the March 1 2026 deadline. Eligible sites must be stand‑alone plants, located in the United States or its territories, and commit to...

By FDA Law Blog
Can a Citizen Petition Denial Turn a Warning Letter Into Final Agency Action? The Curious Case of Hybrid Pharma
News•Feb 12, 2026

Can a Citizen Petition Denial Turn a Warning Letter Into Final Agency Action? The Curious Case of Hybrid Pharma

The Southern District of Florida held that a denial of a citizen petition transforms the underlying FDA warning letters into final agency action, allowing judicial review. Hybrid Pharma sued after the FDA refused to rescind two warning letters and the...

By FDA Law Blog
ACI’s 22nd Annual Paragraph IV Disputes: Elevate Your 2026 Hatch-Waxman Strategy
News•Feb 11, 2026

ACI’s 22nd Annual Paragraph IV Disputes: Elevate Your 2026 Hatch-Waxman Strategy

The American Conference Institute will host its 22nd Annual Paragraph IV Disputes Conference on April 21‑22, 2026 in New York’s Times Center. The two‑day forum gathers brand‑name and generic drug stakeholders to discuss Hatch‑Waxman litigation strategies, recent case law, and evolving PTAB practices. Featured...

By FDA Law Blog
Sixth Circuit Affirms Steep Sentence in FDC Act Counterfeiting Case
News•Feb 9, 2026

Sixth Circuit Affirms Steep Sentence in FDC Act Counterfeiting Case

The Sixth Circuit Court of Appeals affirmed a 90‑month prison term for Omar Wala, who pleaded guilty to conspiring to manufacture and distribute counterfeit generic alprazolam pills on the dark web. The court upheld the district court’s fraud loss calculation,...

By FDA Law Blog